Revenue

As attackers arm themselves with AI, a new breed of defense is emerging. Zimperium's recent leadership nod reveals a critical shift to embedded AI security.

Hitachi's Young Leaders Initiative is more than a conference; it's a strategic investment in Asia's future. Here's how it turns theory into practice.

A new study reveals the biggest planning mistake in enterprise IT is rigid strategy. For companies betting on digital transformation, adaptability is now survival.

Sameer Kanodia’s back-to-back CEO awards are more than accolades. They signal a systemic shift where people-centric culture is the new engine of global growth.

Vision Marine's extended partnership with Nextfour isn't just a supply deal; it's a strategic move to define the user experience in electric boating.

In a market drowning in price wars, one LED maker is thriving by rejecting scale for strategy. Absen's focus on value and efficiency offers a blueprint for survival.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

ChipMOS Technologies' May revenue surged 17.7% year-over-year, fueled by AI chip demand. Despite a minor monthly dip, the firm is expanding capacity.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

Questex's Fierce Biotech is launching a UK event, but this is more than expansion. It’s a calculated bet on London's future as a biotech superpower.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

A landmark deal locks in energy for Ukraine and Finland until 2044, cementing a small Baltic terminal as a powerhouse of European strategic resilience.

A new campaign pairs a star athlete with a robotic mower, revealing a deeper strategy to win the multi-billion-dollar race for autonomous home care.

A new study by SciBase and Castle Biosciences is testing technology to predict atopic dermatitis flares, promising a shift from reactive care to patient control.

A global health giant is now targeting the world's financial system, arguing that crippling debt is a deadlier crisis than any disease. Is their plan a revolution or a fantasy?

In just two years, AIKO Energy has captured a significant slice of Australia's solar market. We dissect the strategy combining breakthrough tech and local focus.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

A new routing model promises to solve the persistent liquidity and execution problems plaguing the $31B tokenized asset market. Is this the key?

Akkodis is betting on 3D-printed wings and AI-powered inspections to make existing aircraft fleets greener, safer, and more efficient.

As illicit tobacco and vapes flood India, Big Tobacco calls for a crackdown. But is this a genuine partnership or a strategic play in a global shadow economy?